M. Prieto
University of Salamanca
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by M. Prieto.
Autoimmunity | 2006
Eduardo Cabrera-Rode; Gisela Molina; Celeste Arranz; Manuel Vera; Pedro Gonzalez; Rolando Suárez; M. Prieto; Saúl Padrón; Rafael León; Juana Tillan; Igrid García; Claudio Tiberti; Olga María Rodríguez; Antonio Jesús Díaz Gutiérrez; Tamara Fernández; Amparo Govea; José Manuel Hernández; Dania Chiong; Emma Domínguez; Umberto Di Mario; Oscar Díaz-Díaz; Oscar Díaz-Horta
Background: Nicotinamide has been used with success to prevent type 1 diabetes in animal models and humans. This vitamin B3 derivative has attracting effects on β-cell protection and regeneration. Aim/hypothesis: To evaluate the effect of standard nicotinamide administration on type 1 diabetes prevention in first degree relatives of persons with type 1 diabetes as well as on the concentrations of islet-cell-related autoantibodies, insulin secretion and peripheral sensitivity. Subjects and methods: A randomized double-blind placebo controlled intervention trial was conducted in 40 first degree relatives of type 1 diabetic patients. Persistence of ICA ( ≥ 10 JDF units) was among inclusion criteria. Participants were randomly allocated oral standard nicotinamide (1.2 g/m2) or placebo for 5 years. Groups were also stratified by age. Islet associated antibodies, fasting blood glucose, fasting plasma insulin concentrations, OGTT, IVGTT and HLA-DR genotyping were performed in all participants. The main criterion to stop treatment was type 1 diabetes development as defined by WHO. Results: Type 1 diabetes development frequencies were similar between the treatment groups. ICA frequencies at the end of the study, first phase insulin release, and insulin sensitivity did not differ between groups as well. None of the participants suffered from any adverse events described for nicotinamide. Conclusions: Type 1 diabetes prevention trial using standard nicotinamide is feasible but fails to prevent or delay the disease onset at the dose we used.
Journal of the International AIDS Society | 2008
M Hojman; F Murano; G Manonelles; M Maldonado; N Ahmed; M Sanchez Vera; M. Prieto
Purpose of the study HIV maternal-fetal transmission (MFT-HIV) in Argentina is around 6%, one of the highest rates in Latin America. Most cases occur in the outskirts of Buenos Aires, a highly populated, low resources setting where the hospitals of this study are located. Our objective was to assess reasons, risk factors and percentage of MFT-HIV, characteristics of HIV+ pregnant women (PW), and evaluation of preventive measurements.
Journal of Medical Virology | 2005
Eduardo Cabrera-Rode; Luis Sarmiento; Gisela Molina; Cecilia Pérez; Celeste Arranz; José A. Galvan; M. Prieto; Julio Barrios; Rosa Palomera; Magile Fonseca; Pedro Mas; Oscar Díaz-Díaz; Oscar Díaz-Horta
Toxicology Letters | 2016
Laura Vicente-Vicente; F.J. Sanz-Parras; A.G. Casanova-Paso; M.T. Hernández-Sánchez; M. Pescador; M. Prieto; A.I. Morales
Toxicology Letters | 2016
Laura Vicente-Vicente; M. Prieto; M. Pescador; A.G. Casanova; M.T. Hernández-Sánchez; A.I. Morales
Toxicology Letters | 2016
A.G. Casanova; L. Vicente Vicente; M. Prieto; M. Pescador; M.T. Hernández Sánchez; F.E. Almaraz Menéndez; A.I. Morales
Toxicology Letters | 2016
A.G. Casanova; M.T. Hernández Sánchez; M. Prieto; M. Pescador; A.I. Morales; L. Vicente Vicente
Toxicology Letters | 2016
Álvaro Casanova; L. Vicente Vicente; M.T. Hernández Sánchez; M.I. Rihuete; Rubén Darío Nieto; L.M. Ramis; A. Gómez Bernal; S.M. Sancho; M. Prieto; M. Pescador; F.J. López Hernández; Alejandra Morales
Toxicology Letters | 2016
M.T. Hernández Sánchez; L. Vicente Vicente; A.G. Casanova; M. Pescador; M. Prieto; F.J. López Hernández; A.I. Morales
Toxicology Letters | 2016
M.T. Hernández Sánchez; L. Vicente Vicente; F.J. Sanz Parras; A.G. Casanova; M. Pescador; M. Prieto; A.I. Morales